{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:07:09Z","timestamp":1788916029374,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The resistance of doxorubicin (DOX), the first-line chemotherapeutic drug for osteosarcoma (OS), stands as a pivotal obstacle in the effective treatment of OS. Alterations in mitochondrial dynamics and thereby affecting reactive oxygen species (ROS) accumulation play critical roles in DOX-induced cell death. However, the novel targets and pharmacological agents combating DOX resistance in OS via mitochondrial homeostasis and DOX-induced cell death manipulation is poorly understood. Herein, we showed that the C\/EBP\u03b1\/GREM1\/p-ERK signaling pathway sensitizes OS to DOX by promoting mitochondrial fission and causing ROS-induced apoptosis. C\/EBP\u03b1 agonist ICCB280 and ERK pathway inhibitor PD98059 both played a DOX sensitivity augmentation role in OS in vitro and in vivo. The combined application of these two agents synergistically amplifies the cytotoxic impact of DOX, potentially overcoming DOX resistance and offering innovative therapeutic strategies for treating DOX-resistant OS.<\/jats:p>","DOI":"10.1038\/s41419-026-08980-y","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:45:56Z","timestamp":1782369956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["C\/EBP alpha agonist ICCB280 overcomes doxorubicin resistance in osteosarcoma through mitochondrial dynamics-dependent GREM1-MAPK activation"],"prefix":"10.1038","volume":"17","author":[{"given":"Yuchen","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2312-7189","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyuan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0697-5108","authenticated-orcid":false,"given":"Yimeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1675-7003","authenticated-orcid":false,"given":"Jianxiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-070X","authenticated-orcid":false,"given":"Wenchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"8980_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, et al. Osteosarcoma. Nat Rev Dis Primers. 2022;8:77.","journal-title":"Nat Rev Dis Primers"},{"key":"8980_CR2","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","volume":"33","author":"MS Isakoff","year":"2015","unstructured":"Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029\u201335.","journal-title":"J Clin Oncol"},{"key":"8980_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-cellbio-120420-015303","volume":"38","author":"K Shen","year":"2022","unstructured":"Shen K, Pender CL, Bar-Ziv R, Zhang H, Wickham K, Willey E, et al. Mitochondria as cellular and organismal signaling hubs. Annu Rev Cell Dev Biol. 2022;38:179\u2013218.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"8980_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41580-020-0210-7","volume":"21","author":"M Giacomello","year":"2020","unstructured":"Giacomello M, Pyakurel A, Glytsou C, Scorrano L. The cell biology of mitochondrial membrane dynamics. Nat Rev Mol Cell Biol. 2020;21:204\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8980_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-pathmechdis-012419-032711","volume":"15","author":"DC Chan","year":"2020","unstructured":"Chan DC. Mitochondrial dynamics and its involvement in disease. Annu Rev Pathol. 2020;15:235\u201359.","journal-title":"Annu Rev Pathol"},{"key":"8980_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cmet.2015.06.006","volume":"22","author":"PH Willems","year":"2015","unstructured":"Willems PH, Rossignol R, Dieteren CE, Murphy MP, Koopman WJ. Redox homeostasis and mitochondrial dynamics. Cell Metab. 2015;22:207\u201318.","journal-title":"Cell Metab"},{"key":"8980_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119527","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278:119527.","journal-title":"Life Sci"},{"key":"8980_CR8","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/ph14090923","volume":"14","author":"M Argenziano","year":"2021","unstructured":"Argenziano M, Tortora C, Pota E, Di Paola A, Di Martino M, Di Leva C, et al. Osteosarcoma in children: not only chemotherapy. Pharmaceuticals (Basel). 2021;14:923.","journal-title":"Pharmaceuticals (Basel)"},{"key":"8980_CR9","first-page":"84","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta. 2014;1845:84\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"8980_CR10","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1158\/0008-5472.CAN-24-0163","volume":"84","author":"W Zhang","year":"2024","unstructured":"Zhang W, Li W, Yin C, Feng C, Liu B, Xu H, et al. PRKDC induces chemoresistance in osteosarcoma by recruiting GDE2 to stabilize GNAS and activate AKT. Cancer Res. 2024;84:2873\u201387.","journal-title":"Cancer Res"},{"key":"8980_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115433","volume":"296","author":"X Ma","year":"2022","unstructured":"Ma X, Suo Z, Ma X, Zhan C, Luo G, Song J. Cinobufagin inhibits tumor progression and reduces doxorubicin resistance by enhancing FOXO1-mediated transcription of FCGBP in osteosarcoma. J Ethnopharmacol. 2022;296:115433.","journal-title":"J Ethnopharmacol"},{"key":"8980_CR12","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.3390\/molecules27144478","volume":"27","author":"S Peter","year":"2022","unstructured":"Peter S, Alven S, Maseko RB, Aderibigbe BA. Doxorubicin-based hybrid compounds as potential anticancer agents: a review. Molecules. 2022;27:4478.","journal-title":"Molecules"},{"key":"8980_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115455","volume":"137","author":"GM Todd","year":"2020","unstructured":"Todd GM, Gao Z, Hyv\u00f6nen M, Brazil DP, Ten Dijke P. Secreted BMP antagonists and their role in cancer and bone metastases. Bone. 2020;137:115455.","journal-title":"Bone"},{"key":"8980_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.tcb.2014.12.004","volume":"25","author":"DP Brazil","year":"2015","unstructured":"Brazil DP, Church RH, Surae S, Godson C, Martin F. BMP signalling: agony and antagony in the family. Trends Cell Biol. 2015;25:249\u201364.","journal-title":"Trends Cell Biol"},{"key":"8980_CR15","first-page":"1419","volume":"38","author":"R Honma","year":"2018","unstructured":"Honma R, Sakamoto N, Ishikawa A, Taniyama D, Fukada K, Hattori T, et al. Clinicopathological and prognostic significance of epithelial gremlin1 expression in gastric cancer. Anticancer Res. 2018;38:1419\u201325.","journal-title":"Anticancer Res"},{"key":"8980_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0467-7","volume":"17","author":"U Neckmann","year":"2019","unstructured":"Neckmann U, Wolowczyk C, Hall M, Almaas E, Ren J, Zhao S, et al. GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. Cell Commun Signal. 2019;17:140.","journal-title":"Cell Commun Signal"},{"key":"8980_CR17","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.18632\/oncotarget.23750","volume":"9","author":"S Shaik","year":"2018","unstructured":"Shaik S, Kennis B, Maegawa S, Schadler K, Yanwen Y, Callegari K, et al. REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget. 2018;9:5233\u201350.","journal-title":"Oncotarget"},{"key":"8980_CR18","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/onc.2009.493","volume":"29","author":"MR Morris","year":"2010","unstructured":"Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010;29:2104\u201317.","journal-title":"Oncogene"},{"key":"8980_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00535-012-0614-z","volume":"48","author":"MH Chen","year":"2013","unstructured":"Chen MH, Yeh YC, Shyr YM, Jan YH, Chao Y, Li CP, et al. Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. J Gastroenterol. 2013;48:101\u20138.","journal-title":"J Gastroenterol"},{"key":"8980_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41586-022-04888-7","volume":"607","author":"L Lan","year":"2022","unstructured":"Lan L, Evan T, Li H, Hussain A, Ruiz EJ, Zaw Thin M, et al. GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Nature. 2022;607:163\u20138.","journal-title":"Nature"},{"key":"8980_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111619","volume":"384","author":"Q Gu","year":"2019","unstructured":"Gu Q, Luo Y, Chen C, Jiang D, Huang Q, Wang X. GREM1 overexpression inhibits proliferation, migration and angiogenesis of osteosarcoma. Exp Cell Res. 2019;384:111619.","journal-title":"Exp Cell Res"},{"key":"8980_CR22","doi-asserted-by":"publisher","first-page":"8475","DOI":"10.1096\/fj.201903235R","volume":"34","author":"E Machiela","year":"2020","unstructured":"Machiela E, Liontis T, Dues DJ, Rudich PD, Traa A, Wyman L, et al. Disruption of mitochondrial dynamics increases stress resistance through activation of multiple stress response pathways. Faseb J. 2020;34:8475\u201392.","journal-title":"Faseb J"},{"key":"8980_CR23","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1038\/s41388-020-1168-9","volume":"39","author":"SS Chauhan","year":"2020","unstructured":"Chauhan SS, Toth RK, Jensen CC, Casillas AL, Kashatus DF, Warfel NA. PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer. Oncogene. 2020;39:2597\u2013611.","journal-title":"Oncogene"},{"key":"8980_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2016.82","volume":"2","author":"G Casinelli","year":"2016","unstructured":"Casinelli G, LaRosa J, Sharma M, Cherok E, Banerjee S, Branca M, et al. N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics. Cell Death Discov. 2016;2:16082.","journal-title":"Cell Death Discov"},{"key":"8980_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13046-018-0772-9","volume":"37","author":"HJ Park","year":"2018","unstructured":"Park HJ, Bae JS, Kim KM, Moon YJ, Park SH, Ha SH, et al. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. J Exp Clin Cancer Res. 2018;37:107.","journal-title":"J Exp Clin Cancer Res"},{"key":"8980_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3109\/07357907.2011.606252","volume":"29","author":"F Luk","year":"2011","unstructured":"Luk F, Yu Y, Walsh WR, Yang JL. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. Cancer Investig. 2011;29:521\u201332.","journal-title":"Cancer Investig"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08980-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08980-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08980-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:37:03Z","timestamp":1788914223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08980-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8980"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08980-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"783"}}